Single walled carbon nanotube/sirna complexes and methods related thereto
View Patent ↗The present invention includes single-walled carbon nanotube compositions for the delivery of bioactive agents and methods of making such single-walled carbon nanotube compositions.
1. A method for delivering siRNA to tumorigenic tissue comprising:
administering via intravenous injection to a subject having tumorigenic tissue an effective amount of a pharmaceutical composition comprising
one or more short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes; and
a pharmaceutically acceptable excipient;
administering one or more subsequent doses of the pharmaceutical composition about every 12 to 24 hours based on effect without regard to blood plasma concentration levels of the short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes.
2. The method of claim 1 , wherein the subject is selected from a mammal, a mouse, and a human.
3. The method of claim 1 , wherein the subject is a human having cancer.
4. The method of claim 1 , wherein the effective amount comprises up to about 100 mg of the one or more short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes.
5. The method of claim 1 , wherein the effective amount comprises up to about 30 mg of the one or more short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes.
6. The method of claim 1 , wherein the effective amount comprises from about 15 mg to about 100 mg of the one or more short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes.
7. The method of claim 1 , wherein the effective amount comprises from about 15 mg to about 30 mg of the one or more short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes.
8. The method of claim 1 , wherein a substantial portion of the one or more short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes accumulates in the tumorigenic tissue at sufficient concentrations to inhibit expression of at least one target associated with the one or more short-interfering ribonucleic acid (siRNA)tissue within about 1 hour after administration.
9. The method of claim 1 , wherein substantially none of the one or more short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes are in circulation from about 5 to about 15 minutes after administration of the one or more short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes.
10. The method of claim 1 , wherein the effective amount of one or more short-interfering ribonucleic acid (siRNA) is non-covalently complexed to single-walled carbon nanotubes.
11. A method for inhibiting expression of a gene in a subject comprising:
administering to the subject an effective amount of a pharmaceutical composition comprising:
an effective amount of one or more short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes; and
a pharmaceutically acceptable excipient;
and administering one or more subsequent doses of the pharmaceutical composition about every 12 to 24 hours based on effect without regard to blood plasma concentration levels of the short-interfering ribonucleic acid (siRNA) complexed to single-walled carbon nanotubes.
12. A method for delivering siRNA to tumorigenic tissue comprising:
administering via intravenous injection to a subject having tumorigenic tissue a pharmaceutical composition comprising:
an effective amount of one or more short-interfering ribonucleic acid (siRNA) complexed to carbon nanotubes; and
a pharmaceutically acceptable excipient.